An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support this molecule’s approach of addressing what is becoming a competitive inflammation target for heart disease. The data readout also starts the clock on negotiations with a big pharma company that has the inside track for securing rights to the once-daily pill.

Ventyx’s drug, VTX3232, is an oral small molecule designed to block the NLRP3 inflammasome, a protein complex that regulates inflammatory signaling. The main goal of the placebo-controlled Phase 2 study was to evaluate safety and tolerability, and the results reported Wednesday passed that bar. It’s the efficacy measures that are piquing

See Full Page